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Abstract
Observed gonorrhea case rates (number of positive tests per 100,000 individuals) increased
by 75% in the United States between 2009 and 2017, predominantly among men. However,
testing recommendations by the Centers for Disease Control and Prevention (CDC) have also
changed over this period with more frequent screening for sexually transmitted infections (STIs)
recommended among men who have sex with men (MSM) who are sexually active. In this and
similar disease surveillance settings, a common question is whether observed increases in the
overall proportion of positive tests over time is due only to increased testing of diseased indi-
viduals, increased underlying disease or both. By placing this problem within a counterfactual
framework, we can carefully consider untestable assumptions under which this question may be
answered and, in turn, a principled approach to statistical analysis. This report outlines this
thought process.
1 Introduction
Observed gonorrhea case rates (number of positive tests per 100,000 individuals) increased by 75%
in the United States between 2009 and 2017 [Centers for Disease Control and Prevention, 2018],
predominantly among men. However, testing recommendations by the Centers for Disease Con-
trol and Prevention (CDC) have increasingly emphasized more frequent screening for sexually
transmitted infections (STIs) among men who have sex with men (MSM) who are sexually active
[Centers for Disease Control and Prevention, 2010, 2015]. In 2014, CDC also recommended STI
screening every six months for users of HIV preexposure prophylaxis (PrEP)[Centers for Disease Control and Prevention,
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2014] and updated their guidelines to recommend screening PrEP users every three months in
2017[Centers for Disease Control and Prevention, 2017].
In this and similar disease surveillance settings, a common question is whether observed in-
creases in the overall proportion of positive tests over time is due to increased targeted screening
efforts (i.e. increased chance of identifying disease in sick individuals), increased underlying disease
(the population is getting sicker over time) or both. Answering this question requires knowledge
of quantities that cannot be generally identified (and, in turn, estimated) without untestable as-
sumptions. We can rely on results from the causal inference literature [Herna´n et al., 2004, Pearl,
1995, Herna´n and Robins, 2018] and the related missing data literature [Little and Rubin, 2002],
to explicitly consider these untestable assumptions and, in turn, inform an appropriate analytic
approach.
2 The observed data and observable quantities
Consider a time period of interest divided into equally spaced intervals. Define nt as the total
number of individuals in the study population of interest (e.g. men in the United States) at the
start of interval t. We allow that each interval t study population may consist of different individuals
with some individuals members of the population at multiple times.
Assume we observe the following for each individual i = 1, . . . , nt in each interval t study pop-
ulation. Suppressing the individual i subscript, denote St as an indicator of whether the individual
is tested for a disease (e.g. gonorrhea) in that interval and Zt as a vector of pre-test disease risk
factors for that individual (e.g. number of previous STIs and STI tests, previous HIV tests, age,
race, PrEP use). Denote Yt as an indicator of whether an individual has that disease in interval t.
For individuals without a test in interval t (St = 0), disease status Yt is unobserved. We rely on
the temporal order assumption (Zt, St, Yt).
We make the simplifying assumptions that if St = 1 then Yt is known, no subject in each interval
t study population dies or is lost to follow-up before the end of the interval and screening/testing
does not affect disease status within an interval (e.g. it cannot affect behavior change). These
assumptions could be guaranteed for increasingly short intervals (e.g. hours or days) but are not
guaranteed for longer intervals (e.g. years). Finally, we assume no measurement error, including
100% sensitivity and specificity of the test. The ideas presented here can in principle be extended to
accommodate more complicated settings. For example, see X. Garc´ıa-Albe´niz and Herna´n [2017],
Herna´n et al. [2009], S.A. Swanson, Ø Holme, M Løbergand, M. Kalager, M. Bretthauer, G. Hoff, E. Aas and M.A. Herna´n
[2015], Neugebauer et al. [2017].
In the current setting, we require no untestable assumptions in order to confirm whether the
population chance of receiving a test in any interval t, which we can denote Pr[St = 1], is increasing
with time t. In each interval t this chance can be estimated via the sample proportions
ns,t
nt
where ns,t =
∑nt
i=1 Si,t (the number of individuals in the population who received a test). These
proportions might be plotted as a function of interval t to observe trends over time which in some
cases may reasonably be summarized by a regression model. A simple model is Pr[St = 1] =
2
exp{β0 + β1t}. Provided this regression model is correctly specified, a value of β1 > 0 would be
consistent with an increasing trend. This model is simple because it assumes Pr[St=1]Pr[St−1=1] is the same
for all t. More complex models that allow more flexible functions of t can also be considered (e.g.
higher order polynomials, splines). A completely flexible model would include separate indicator
terms for each interval in the follow-up. This would allow Pr[St=1]Pr[St−1=1] to differ for all t. Generalized
estimating equations [K. Liang and S. Zeger, 1986] might be used to estimate model coefficients and
construct 95% confidence intervals that account for the fact that some individuals might contribute
to more than one interval t population. Analogously, we can directly observe trends within subsets
of the population defined by a particular level of Zt; i.e., trends in Pr[St = 1|Zt = zt] for some level
Zt = zt. This might be achieved by stratifying regression models on different levels of Zt. More
generally, it will require additional regression model assumptions.
We similarly require no untestable assumptions in order to infer whether the prevalence of
disease conditional on being tested, which we can denote Pr[Yt = 1|St = 1], is increasing with time
t. In each interval t, this chance can also be estimated via sample proportions, here computed as
ny,s,t
ns,t
where ny,s,t =
∑nt
i=1 Yi,tSi,t (the number of individuals in the population who had a positive
test). Similarly, regression models might be used for summarizing the trends and robust methods
used for variance estimation, possibly with further conditioning on Zt.
The overall chance of a positive test is the joint population chance that Yt = 1 and St = 1
(having disease and having a test) or Pr[Yt = 1, St = 1]. This quantity is also observed in this
setting and could be estimated via the sample proportion
ny,s,t
nt
, the number of individuals in interval
t with disease and a test divided by the total in the population at t. We would like to understand
whether increases in this quantity are explained by increased testing in diseased individuals or
increased underlying disease.
3 More disease?
An answer to our question minimally requires knowledge of a quantity that we do not directly
observe in any interval t: the prevalence of disease in the whole interval t population for each t.
This quantity is not directly observable because disease status Yt is not observed if an individual
does not receive a test (St = 0). Relative to the observed data, we can understand this question in
terms of time trends in a counterfactual probability.
Specifically, let Y st=1t denote the disease indicator we would have observed for an individual in
the interval t population had, possibly contrary to fact, that individual received a test in interval
t. In turn, the underlying population disease prevalence for interval t had we implemented a
hypothetical intervention to ensure everyone in the population was tested is
Pr[Y st=1t = 1]. (1)
Unlike the quantities considered in the previous section, we cannot directly assess trends in Pr[Y st=1t =
1] as a function of time t as these probabilities cannot be known without assumptions. We allow
that interest might also be in trends in subsets of the population defined by a subset Vt of the
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covariates Zt
Pr[Y st=1t = 1|Vt] (2)
where a special case is Vt = Zt (i.e. the subset is the whole set of covariates). In the next section
we consider untestable assumptions under which these generally unobservable quantities and their
corresponding trends in t can be identified using only the observed data.
3.1 Identifying assumptions
Suppose the following assumptions hold for each interval t population:
1. Conditional exchangeability: Y st=1
∐
St|Zt
This assumption requires that, within levels of measured baseline covariates, whether or not
someone receives a test in interval t is independent of his underlying disease status that we
would observe had he been screened. Conditional exchangeability may be alternatively refer-
enced as the assumption of no unmeasured selection bias with Zt referred to as the measured
selection factors [Herna´n and Robins, 2018] and also coincides with a missing at random
(MAR) assumption [Little and Rubin, 2002]. Conditional exchangeability is guaranteed un-
der an intervention on St where the investigators flipped a weighted coin dependent only on
Zt to determine who does and does not receive a test. However, in the absence of intervention
on St, this assumption is not guaranteed to hold.
2. Positivity: If Pr[Zt = zt] > 0 then Pr[St = 1|Zt = zt] > 0
This assumption requires that, if a particular level of the baseline covariates Zt = zt is possible
to observe in the interval t population, then it must also be possible for individuals with that
level of the baseline covariates to receive a test.
3. Consistency: If St = 1 then Y
st=1 = Yt
This assumption states that, if a subject is observed to receive a test, then his observed
disease status is equal to his counterfactual disease status. Consistency requires well-defined
interventions [Herna´n, 2016], implying the so-called stable unit treatment value assumption
(SUTVA)[Rubin, 1986] which includes the assumptions of “no multiple versions of treatment”
and “no interference between units” (i.e., one individual’s treatment does not affect a different
individual’s counterfactual outcome). Consistency holds under the simplifying assumption
that screening cannot affect disease status within interval t but is not generally guaranteed.
Figure 1 depicts a causal directed acyclic graph (DAG) representing a possible data generating
assumption on the observed data in interval t described in Section 2 with the t subscripts suppressed.
In this graph, assume Z1 (e.g. race, age), Z2 (e.g. a prior rectal STI test) and Z3 (STI symptoms)
comprise the vector of measured covariates Z while U1 (e.g. previous condomless sex) and U2
(e.g. previously undiagnosed disease) represent unmeasured risk factors for current disease status
in interval t. Paths on the graph connecting two nodes via only directed arrows represent causal
paths. For example, the path Z3 → S represents the assumption that disease symptoms could affect
an individual’s chance of receiving a test for the disease. By contrast, the path Z3 ← U2 → Y is
4
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Figure 1: A causal DAG representing observed data generating assumptions under which we may
identify the counterfactual disease prevalence had all individuals been tested Pr[Y st=1t = 1]. No
unblocked backdoor paths (noncausal paths) connecting testing S to disease Y conditional only on
measured covariates Z1, Z2, Z3
an example of an “unblocked backdoor” (noncausal) path, which represents the assumption that
disease symptoms are associated with current disease status via their common cause, “previously
undiagnosed disease”. The assumption of conditional exchangeability, or no unmeasured selection
bias, is consistent with the assumptions of Figure 1 by the absence of any unblocked backdoor paths
connecting S and Y conditional on Z1, Z2 and Z3 only [Pearl, 1995, Richardson and Robins, 2013].
This assumption would fail if symptoms Z3 were unmeasured (and therefore not a component of
the measured covariate vector Z). Alternatively, this assumption would fail if previous condomless
sex U1 directly affected the individual’s decision to receive a test (which would be represented by
adding an arrow from U1 into S).
Given conditional exchangeability, consistency and positivity, it is straightforward to show that
our counterfactual probability of interest Pr[Y st=1t = 1] can be written as a function of only the
observed data: ∑
zt
Pr[Yt = 1|St = 1, Zt = zt] Pr[Zt = zt] (3)
The expression (3) is a special case of Robins’s g-formula 1986. The expression can be most simply
understood as a weighted sum of the chance of having disease conditional on receiving a test and
covariate level Zt = zt over all possible levels, weighted by the chance of that covariate level
occurring in the interval t population. When Zt contains any continuous components, the sum
would be replaced with an integral.
Note that, in the special case where marginal exchangeability holds, rather than conditional
exchangeability, such that Y st=1
∐
St|Zt for Zt = ∅ (the empty set), then the expression (3)
reduces simply to the chance of a positive test amongst those tested Pr[Yt = 1|St = 1]. This
stronger exchangeability assumption would hold, for example, under an unrealistically restrictive
version of Figure 1 in which we removed all arrows from Z1, Z2, Z3 into S. Finally, note that our
three identifying assumptions also give identification of the conditional counterfactual probability
(2) as a function of only the observed data. We discuss this further in the next section where we
consider estimating these functions and their time trends in practice where Zt is typically high-
dimensional.
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3.2 Estimation
For the purposes of practical estimation and the assessment of trends in time t, it is useful to note
that the expression (3) is algebraically equivalent to the weighted mean
E
[
YtSt
Pr[St = 1|Zt]
]
(4)
where E[] denotes expectation (population mean). This weighted representation suggests a straight-
forward approach to estimating trends in the true underlying Pr[Y st=1t = 1] via a weighted extension
of regression modeling for estimating trends in the chance of a positive test Pr[Yt = 1|St = 1] we
considered in Section 2. In particular, we might use a weighted implementation of generalized
estimating equation methodology [Rotnitzky et al., 1998] to estimate trends in (4) as a function of
t, which will give trends in Pr[Y st=1t = 1] under our identifying conditions. As above, we might
make restrictive assumptions about these trends, such as
Pr[Y st=1t = 1] = exp{ψ0 + ψ1t}
Analogously, provided this regression model is correctly specified, a value of ψ1 > 0 would be consis-
tent with an increasing trend in the true underlying disease prevalence under our three identifying
assumptions. By contrast, a value of ψ = 0 would be consistent with no change in the underlying
prevalence. This model is simple because it assumes that
Pr[Y
st=1
t =1]
Pr[Y
st−1=1
t−1
=1]
, is the same for all t. Again,
more complex models that allow more flexible functions of t can also be considered (e.g. higher
order polynomials, splines). A completely flexible model would include separate indicator terms
for each interval t over the time period. This would allow
Pr[Y
st=1
t =1]
Pr[Y
st−1=1
t−1
=1]
to differ for all t. The
weights in this implementation will take the value 0 for all individuals who did not receive a test.
For individuals who did receive a test, the weight is defined as the inverse probability of receiving a
test in the interval t population given that individual’s level of the covariates Zt. This probability
might itself be estimated via regression modeling (e.g. a logistic regression model) when Zt is high-
dimensional. Note that all individuals, including those who did not receive a test, will contribute
to the estimation of Pr[St = 1|Zt] for the weight denominator. Stabilized weights may alternatively
be used that additionally multiply the weight numerator by an estimate of Pr[St = 1]. The use of
stabilized weights may increase precision [Robins et al., 2000].
If interest is in trends in the conditional prevalence Pr[Y st=1t = 1|Vt] for some subset Vt of the
baseline measured selection factors Zt, then either (i) the regression model fit can be restricted to
one level of Vt of interest (e.g. younger men) or (ii) the regression model can include terms for Vt in
addition to t. A simple, yet restrictive, example for Vt selected to only include the covariate “age”
taking the value 1 if an individual is below age 25 and 0 otherwise is
Pr[Y st=1t = 1|age] = exp{ψ0 + ψ1t+ ψ2age}
This model is restrictive, not only in the assumption of linearity in t but also in that it assumes
that trends are the same regardless of the level of (discretized) age. This assumption might be
relaxed by including an interaction term between t and the covariate “age”. When we consider
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trends in Pr[Y st=1t = 1|Vt] which conditions on Vt, stabilized weights may be used that multiply the
weight numerator by an estimate of Pr[St = 1|Vt]. Finally, if we selected Vt to include all selection
factors Zt, then trends in Pr[Y
st=1
t = 1|Vt] = Pr[Y
st=1
t = 1|Zt] may be estimated via unweighted
regression modeling but with additional inclusion of all covariates Zt in the model along with t.
4 More testing among the diseased?
In the previous section we outlined untestable assumptions under which we may identify and
estimate changes in underlying disease prevalence over time where we can define this prevalence
by the counterfactual quantity Pr[Y st=1 = 1]. Note that, by probability rules, we can write the
overall chance of a positive test Pr[Yt = 1, St = 1] as the product Pr[St = 1|Yt = 1]Pr[Yt = 1] where
Pr[Yt = 1] = Pr[Y
st=1 = 1], the underlying disease prevalence, under our assumption that screening
in interval t cannot affect disease status in that interval (for each individual, his outcome in the
actual world in interval t is equal to the outcome he would have had if, possibly contrary to fact,
he was screened in that interval). The other probability in this product Pr[St = 1|Yt = 1] is the
chance of receiving a test among those with disease. An increase in this quantity over time means
that diseased people have an increasing chance of their disease being identified; a likely result of
increased and targeted screening efforts.
Trends in Pr[St = 1|Yt = 1] might be assessed by trends in
Pr[Yt=1,St=1]
Pr[Yt=1]
. By above argu-
ments, the numerator is directly observed and the denominator is identifiable under the outlined
assumptions. In the special case where marginal exchangeability holds then we have the equality
Pr[St = 1|Yt = 1] = Pr[St = 1] such that trends in this quantity can be directly estimated as in
Section 2. However, as above, marginal exchangeability is not consistent with the causal DAG in
Figure 1 (and will not generally be realistic) due to the unblocked backdoor paths through measured
and unmeasured covariates connecting Yt and St. However, under conditional exchangeability, we
can conclude that Pr[St = 1|Yt = 1, Zt] = Pr[St = 1|Zt] which can be directly estimated.
5 Conclusions
In this report, we considered an approach to understanding assumptions under which we can
evaluate using only observed variables whether increases in testing positivity over time are due
only to increased testing among the disease, increased population disease prevalence or both. We
showed how causal diagrams can be useful for understanding these assumptions and for determining
an analytic approach.
6 Acknowledgements
The authors thank AdamM. Young for helpful discussions. This activity was funded by the Division
of STD Prevention, Centers for Disease Control and Prevention, through the STD Surveillance
7
Network (CDC-RFA-PS13-1306). Support was also provided by the Massachusetts Department of
Public Health. JLM also received funding from National Institute of Allergy and Infectious Diseases
(K01 AI122853).
References
Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines,
2010. MMWR, 59(RR-12):1–110, 2010.
Centers for Disease Control and Prevention. US Public Health Service: Preexposure prophylaxis
for the prevention of HIV infection in the United States – 2014 clinical practice guideline. 2014.
URL https://www.cdc.gov/hiv/pdf/guidelines/PrEPguidelines2014.pdf.
Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines,
2015. MMWR, 64(3):1–137, 2015. URL https://www.cdc.gov/std/tg2015/default.htm.
Centers for Disease Control and Prevention. US Public Health Service: Pre-
exposure prophylaxis for the prevention of HIV infection in the United
States – 2017 Update: a clinical practice guideline. 2017. URL
https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.
Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017. At-
lanta: U.S. Department of Health and Human Services, 2018.
M. A. Herna´n. Does water kill? A call for less casual causal inferences. Annals of Epidemiology,
10:674–80, 2016.
M. A. Herna´n and J.M. Robins. Causal Inference. CRC Press, 2018. URL
https://www.hsph.harvard.edu/miguel-hernan/causal-inference-book/. forthcoming.
M A Herna´n, S Herna´ndez-Dia´z, and J M Robins. A structural approach to selection bias. Epi-
demiology, 15:615–625, 2004.
M. A. Herna´n, M. McAdams, N. McGrath, E. Lanoy, and D. Costagliola. Observation plans in
longitudinal studies with time-varying treatments. Statistical Methods in Medical Research, 18
(1):27–52, 2009.
K. Liang and S. Zeger. Longitudinal Data Analysis Using General Linear Models. Biometrika, 73
(1):13–22, 1986.
R.J.A. Little and D.B. Rubin. Statistical Analysis with Missing Data. John Wiley & Sons, New
York, 2002.
R. Neugebauer, J.A Schmittdiel, A.S. Adams, R.W. Grant RW, and M.J. van der Laan. Iden-
tification of the joint effect of a dynamic treatment intervention and a stochastic monitoring
intervention under the no direct effect assumption. Journal of Causal Inference, 5(1), 2017.
J. Pearl. Causal diagrams for empirical research. Biometrika, 82:669–710, 1995.
8
T. S. Richardson and J. M. Robins. Single World Intervention Graphs (SWIGs): a
unification of the counterfactual and graphical approaches to causality. Center for
Statistics and the Social Sciences, University of Washington Series, 2013. URL
http://www.csss.washington.edu/Papers/. Working Paper Number 128.
J. M. Robins. A new approach to causal inference in mortality studies with a sustained exposure
period: application to the healthy worker survivor effect. Mathematical Modelling, 7:1393–1512,
1986. [Errata (1987) in Computers and Mathematics with Applications 14, 917-921. Addendum
(1987) in Computers and Mathematics with Applications 14, 923-945. Errata (1987) to addendum
in Computers and Mathematics with Applications 18, 477.].
J. M. Robins, M. A. Herna´n, and B. Brumback. Marginal structural models and causal inference
in epidemiology. Epidemiology, 11(5):550–560, 2000.
A. Rotnitzky, J.M. Robins, and D.O. Scharfstein. Semiparametric Regression for Repeated Out-
comes with Nonignorable Nonresponse. Journal of the American Statistical Association, 93(444):
1321–1339, 1998.
D.B. Rubin. Statistics and causal inference: Comment: Which ‘ifs’ have causal answers. Journal
of the American Statistical Association, 81:961–2, 1986.
S.A. Swanson, Ø Holme, M Løbergand, M. Kalager, M. Bretthauer, G. Hoff, E. Aas and M.A.
Herna´n. Bounding the per-protocol effect in randomized trials: an application to colorectal
cancer screening. Trials, 16(541), 2015.
J. Hsu X. Garc´ıa-Albe´niz and M.A. Herna´n. The value of explicitly emulating a target trial when
using real world evidence: an application to colorectal cancer screening. European Journal of
Epidemiology, 32(6):495–500, 2017.
9
